Cancer immunotherapy represents a paradigm shift in the management of cancer. Recent successes with antibody directed therapies for immune modulators such as CTLA4 and PD1/PDL-1 axis have altered the landscape of systemic therapy for solid and hematologic malignancies. Among various strategies to improve cancer immunotherapy, epigenetic targets have emerged as prominent actionable targets to enhance anti-tumor immune [...]